Evidence map›Paper›PMID 23341997›Full record

ArticlePloS one2013

Polymorphisms in the gene regions of the adaptor complex LAMTOR2/LAMTOR3 and their association with breast cancer risk.

Mariana E De Araujo, Gertraud Erhart, Katharina Buck, Elisabeth Müller-Holzner, Michael Hubalek, Heidelinde Fiegl, Daniele Campa, Federico Canzian, Ursula Eilber, Jenny Chang-Claude and 11 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 3 countries.

Mariana E De AraujoDivision of Cell Biology, Innsbruck Medical University, Innsbruck, Austria.
Gertraud Erhart
Katharina Buck
Elisabeth Müller-Holzner
Michael Hubalek
Heidelinde Fiegl
Daniele Campa
Federico Canzian
Ursula Eilber
Jenny Chang-Claude
Stefan Coassin
Margot Haun
Lyudmyla Kedenko
Bernhard Paulweber
Roland Reitsamer
Irmgard Himmel
Dieter Flesch-Janys
Claudia Lamina
Florian Kronenberg
Lukas A Huber
Anita Kloss-Brandstätter
Innsbruck Medical University · ATHeidelberg University · DEParacelsus Medical University · ATGerman Cancer Research Center · DEKrankenhaus Meran · ITUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe late endosomal LAMTOR complex serves as a convergence point for both the RAF/MEK/ERK and the PI3K/AKT/mTOR pathways. Interestingly, both of these signalling cascades play a significant role in the aetiology of breast cancer. Our aim was to address the possible role of genetic polymorphisms in LAMTOR2 and LAMTOR3 as genetic risk factors for breast cancer. METHODOLOGY/

resultsWe sequenced the exons and exon-intron boundaries of LAMTOR2 (p14) and LAMTOR3 (MP1) in 50 prospectively collected pairs of cancerous tissue and blood samples from breast cancer patients and compared their genetic variability. We found one single nucleotide polymorphism (SNP) in LAMTOR2 (rs7541) and two SNPs in LAMTOR3 (rs2298735 and rs148972953) in both tumour and blood samples, but no somatic mutations in cancerous tissues. In addition, we genotyped all three SNPs in 296 samples from the Risk Prediction of Breast Cancer Metastasis Study and found evidence of a genetic association between rs148972953 and oestrogen (ER) and progesterone receptor negative status (PR) (ER: OR = 3.60 (1.15-11.28); PR: OR = 4.27 (1.43-12.72)). However, when we additionally genotyped rs148972953 in the MARIE study including 2,715 breast cancer cases and 5,216 controls, we observed neither a difference in genotype frequencies between patients and controls nor was the SNP associated with ER or PR. Finally, all three SNPs were equally frequent in breast cancer samples and female participants (n = 640) of the population-based SAPHIR Study.

conclusionsThe identified polymorphisms in LAMTOR2 and LAMTOR3 do not seem to play a relevant role in breast cancer. Our work does not exclude a role of other not yet identified SNPs or that the here annotated polymorphism may in fact play a relevant role in other diseases. Our results underscore the importance of replication in association studies.

Indexed as

Polymorphism, Single NucleotideAdaptor Proteins, Signal TransducingBreast NeoplasmsCase-Control StudiesComputational BiologyExonsExtracellular Signal-Regulated MAP KinasesFemaleGenetic Predisposition to DiseaseHumansMechanistic Target of Rapamycin Complex 1Middle AgedMultiprotein ComplexesMutationSignal TransductionTOR Serine-Threonine KinasesAdaptor Proteins, Signal TransducingExtracellular Signal-Regulated MAP KinasesLAMTOR2 protein, humanLAMTOR3 protein, humanMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesTOR Serine-Threonine Kinases

Identifiers

PMID23341997
PMCPMC3547070
OpenAlexW2068920072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.